Picard Medical, Inc. (PMI) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 2.38M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.17
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 75
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 75,178,535
• 10 Day Avg. Volume: 2,124,305
• 30 Day Avg. Volume: 2,378,935
• PEG Ratio: -0.39
• Price to Book (P/B): 34.04
• Price to Sales (P/S): 26.11
• P/FCF Ratio: -8.23
• Enterprise Value/Market Cap: 10.00T>
• Enterprise Value/Revenue: 299.59
• Enterprise Value/Gross Profit: 7.41K
• Enterprise Value/Ebitda: -76.17
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $1.00 ▼(-45.05% Downside)
• Action: Reiterated Date: 03/31/26
• Date: Action: Reiterated 03/31/26

The score is held down mainly by weak financial performance—large ongoing losses and accelerating cash burn despite some improvement in gross margin and balance sheet repair. Technicals also remain bearish with negative MACD and the price below key moving averages. Valuation is constrained by losses (negative P/E) and the absence of dividend support.

Positive Factors

Established clinical leadership

A long track record of >2,100 SynCardia implants and documented multi‑year support demonstrates durable clinical validation and real-world device durability. This entrenched clinical experience supports clinician adoption, referral patterns, reimbursement discussions, and a structural market position in total artificial heart therapy.

Negative Factors

Persistent and accelerating cash burn

Substantial negative operating cash flow that worsened year‑over‑year signals structural cash consumption from operations. Unless revenue scales rapidly or costs are permanently reduced, the company will remain reliant on external capital, which constrains long‑term strategic options and increases execution risk.

Picard Medical, Inc. Business Overview & Revenue Model

Company Description

Picard Medical, Inc., through its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company offers SynCardia TAH, an artificial heart for patients that is designed to fun...

Read more

Picard Medical, Inc., through its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company offers SynCardia TAH, an artificial heart for patients that is designed to fun...

Picard Medical, Inc. Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	4.94M	4.39M	5.04M	4.11M
Gross Profit	200.00K	-112.00K	-2.31M	-4.99M
EBITDA	-12.80M	-17.46M	-14.85M	-10.61M
Net Income	-27.00M	-21.05M	-15.57M	-11.17M
Balance Sheet
Total Assets	22.55M	12.11M	11.37M	15.44M
Cash, Cash Equivalents and Short-Term Investments	7.45M	96.00K	244.00K	152.00K
Total Debt	5.97M	20.93M	9.41M	1.96M
Total Liabilities	18.76M	35.84M	14.93M	4.07M
Stockholders Equity	3.79M	-23.74M	-3.55M	11.37M
Cash Flow
Free Cash Flow	-15.67M	-11.87M	-10.64M	-10.75M
Operating Cash Flow	-15.67M	-11.87M	-10.63M	-10.72M
Investing Cash Flow	0.00	0.00	-9.00K	-37.00K
Financing Cash Flow	27.08M	11.74M	10.84M	5.52M

Picard Medical, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AEMD	45 Neutral	$2.79M	-0.28	-191.39%	―	―	76.53%
VTAK	44 Neutral	$2.50M	-115.09	-173.74%	―	82.96%	82.04%
PMI	42 Neutral	―	-4.78	164.49%	―	―	―
VERO	41 Neutral	$562.87K	-0.05	-2268.26%	―	-12.39%	44.61%
HSCS	40 Underperform	$7.32M	-1.29	-220.42%	―	-41.03%	35.71%
AMIX	―	$4.50M	-0.38	-228.82%	―	―	63.87%

Picard Medical, Inc. Corporate Events